Comparison of Heart Failure Cardiogenic Shock patients with Axillary and Femoral Intra-aortic Balloon Pump: A CSWG report.

Objective: To describe the outcomes of patients receiving axillary (Ax) IABP and compare with those receiving Femoral (Fem) IABP for heart failure related cardiogenic shock (HF-CS).

Background: IABPs are traditionally placed via the femoral artery. Single center studies have shown the utility of axillary placement to promote ambulation.

CSWG-SCAI Stages Combined With Machine Learning-Based Phenotypes for Serial Risk Stratification in Cardiogenic Shock.

Background: Cardiogenic shock (CS) severity can be defined by the SCAI (Society for Cardiovascular Angiography and Interventions) stages (A to E), or machine learning-based phenotypes (I: noncongested, II: cardiorenal, III: cardiometabolic).

Objectives: This study aims to evaluate sequential applicability and prognostic relevance of combining SCAI stages and ML-based phenotypes for risk stratification of patients with CS.

Methods: The authors retrospectively applied both classification systems at 6- to 12-hour intervals for the first 72 hours to patients from the multicenter CSWG (Cardiogenic Shock Working Group) registry.

From Struggle to Triumph: A Journey Through SCAI Stages to Myocardial Recovery.

Cardiogenic shock (CS) is a time-sensitive, dynamic, and multifactorial syndrome that can progress quickly to multiorgan failure and become fatal if not addressed urgently. We present a case of a 47-year-old man who presented with non-ST-segment elevation myocardial infarction complicated by cardiogenic shock who was found to have ischemic cardiomyopathy with multivessel coronary artery disease. His clinical course was complicated by hemodynamic collapse requiring escalation of temporary mechanical circulatory support from intra-aortic balloon pump to Impella 5.

The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Scientific Statement from the Heart Failure Society of America and The American Society for Preventive Cardiology.

Heart disease is the leading cause of death worldwide, with heart failure (HF) recognized as its most severe and debilitating manifestation. Though remarkable advancements have led to the establishment of life-saving and quality-of-life-enhancing medical and device-based therapies for HF, HF-related mortality trends have increased over the past decade. To combat this worldwide epidemic, care must evolve so that preventative recommendations are not siloed from HF management.

Clinical management of the Impella 5.5 pump.

The Impella 5.5 (Abiomed, USA) is a catheter-based micro-axial flow pump that has emerged as a vital tool in managing patients with cardiogenic shock (CS). Delivering up to 5.

Renal Dysfunction Across the Spectrum of Cardiogenic Shock: Mechanisms, Clinical Implications, and Therapeutic Strategies.

Purpose Of Review: This review aims to elucidate the complex interplay between cardiogenic shock (CS) and renal function, detailing the mechanisms of kidney injury, identifying risk factors, and providing a framework for the diagnosis and management of acute kidney injury (AKI) in CS. We evaluate evidence supporting medical interventions, including vasopressors, inotropes, and mechanical circulatory support (MCS), in relation to renal outcomes.

Recent Findings: AKI affects up to 80% of patients with CS and is associated with higher mortality, especially when Renal Replacement Therapy (RRT) is required.

2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology.

Obesity confers increased risks of HF, coronary artery disease, and stroke, and weight loss can reduce cardiovascular disease risk. Given emerging evidence of the benefits of semaglutide and tirzepatide in individuals with HFpEF and obesity in concert with healthy behavioral interventions, clinicians should be aware of optimal diagnosis, risk assessment, and management of obesity in individuals with HF. Despite the early promise of anti-obesity medications in HFpEF, challenges remain, including whether BMI is the optimal metric to identify obesity and subsequent benefit from anti-obesity medications; the safety profile of anti-obesity medications for individuals with HF, particularly HFrEF; and whether the benefits of anti-obesity medications are attributed mainly to the magnitude of weight loss or due to other mechanisms of action.

Outcomes With Femoral IABP in Heart Failure and Acute Myocardial Infarction-Related Cardiogenic Shock.

Background: Intra-aortic balloon pump (IABP) insertion has not been shown to improve mortality rates in acute myocardial infarction-related cardiogenic shock (AMI-CS) but is increasingly used in heart failure-related cardiogenic shock (HF-CS).

Objective: We sought to compare IABP-related outcomes in patients with HF-CS and AMI-CS.

Methods: The Cardiogenic Shock Working Group registry was queried for patients with CS receiving femoral IABPs as the first temporary mechanical circulatory support (tMCS) device.

Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop.

Despite substantial advancements in the management of cardiogenic shock, mortality rates remain greater than 40%. Trials have shown that increasing survival rates in cardiogenic shock is challenging. Even the most successful trials show 5-15% reductions in mortality, and gains have been restricted to acute myocardial infarction cardiogenic shock, representing approximately 5% of the population with cardiogenic shock.

Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001: Insights From the ARISE-HF Study.

Background: Diabetic cardiomyopathy (DbCM) is a significant cause of heart failure (HF) in individuals with type 2 diabetes mellitus. Although sex differences are noted in HF patients, it is unclear if such differences exist in those with DbCM and whether sex-based differences affect treatment responses.

Objectives: This analysis focuses on sex differences in baseline characteristics of study participants with DbCM at high risk for progression to overt HF and sex-based treatment responses to high-dose AT-001, a novel aldose reductase inhibitor.

Worsening Renal Function Is Common and Is Associated With Higher Mortality Rates in Cardiogenic Shock: A Cardiogenic Shock Working Group Report.

Background: Outcomes associated with worsening renal function (WRF) in cardiogenic shock (CS) remain poorly understood.

Objectives: To study the incidence of WRF in heart failure-CS (HF-CS) and acute myocardial infarction CS (AMI-CS), examine its association with in-hospital mortality (IHM) rates, define the trajectory of renal function in CS, and identify independent predictors of WRF in HF-CS vs AMI-CS.

Methods: Patients in the Cardiogenic Shock Working Group registry (CSWG) from 2021-2024 were analyzed; those with baseline end-stage renal disease were excluded.

Cardiogenic Shock Teams: Past, Present, and Future Directions.

Cardiogenic shock (CS) remains a significant challenge in cardiovascular medicine, characterized by substantial morbidity and mortality. Historically, patient outcomes in CS have been varied, highly dependent on the timeliness of interventions and the expertise available at treating centers. Emerging evidence indicates that structured, team-based approaches significantly improve survival rates and diminish complications linked to CS.

Race, Sex, and Ejection Fraction-Based Differences in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Risk Prediction.

The early detection of transthyretin cardiac amyloidosis (ATTR-CM) is essential, with Tc-99m pyrophosphate scintigraphy (PYP scan) being a key diagnostic tool. Although a previously validated score has shown promise in predicting PYP scan positivity among patients with HFpEF, further evaluation in diverse cohorts is necessary. To assess the effectiveness of the ATTR-CM score in predicting PYP scan positivity within our patient population.

The Society of Thoracic Surgeons Intermacs 2024 Annual Report: Focus on Outcomes in Younger Patients.

The 15th Annual Report from The Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support includes 29,634 continuous-flow left ventricular assist devices from the 10-year period between 2014 and 2024. The outcomes reported here demonstrate continued improved survival in the current era of fully magnetically levitated devices, with a significantly higher 1-year (85.7% vs 78.

2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures.

This document describes performance measures for heart failure that are appropriate for public reporting or pay-for-performance programs and is meant to serve as a focused update of the "2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures." The new performance measures are taken from the "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines" and are selected from the strongest recommendations (Class 1 or Class 3). In contrast, quality measures may not have as much evidence base and generally comprise metrics that might be useful for clinicians and health care organizations for quality improvement but are not yet appropriate for public reporting or pay-for-performance programs.